Mohamed Omar, Min Gyu Kang, Moon Ki Jung, Jong-Hwa Ahn, Jin-Sin Koh, Phil Iver Guevarra, Sang-Wook Kim, Udaya S Tantry, Paul A Gurbel, Jin-Yong Hwang, Young-Hoon Jeong
{"title":"Association and Prognostic Implications of \"No-Reflow Phenomenon\" and Hypercoagulability in Patients With ST-Segment Elevation Myocardial Infarction.","authors":"Mohamed Omar, Min Gyu Kang, Moon Ki Jung, Jong-Hwa Ahn, Jin-Sin Koh, Phil Iver Guevarra, Sang-Wook Kim, Udaya S Tantry, Paul A Gurbel, Jin-Yong Hwang, Young-Hoon Jeong","doi":"10.1016/j.jacasi.2025.07.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Following percutaneous coronary intervention (PCI), the \"no-reflow phenomenon\" is associated with a worse outcome. However, it remains unclear how to prevent and treat this phenomenon during PCI.</p><p><strong>Objectives: </strong>This study aimed to evaluate the association between thrombogenicity profiles and \"no-reflow phenomenon\" during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI).</p><p><strong>Methods: </strong>From a real-world registry, we prospectively enrolled patients with STEMI who underwent primary PCI (n = 334). Thrombolysis In Myocardial Infarction flow grade was assessed at final angiography, and the \"no-reflow phenomenon\" was defined as Thrombolysis In Myocardial Infarction flow between 0 and 2. Thrombogenicity profiles were assessed with thromboelastography (TEG) and conventional hemostatic measurements.</p><p><strong>Results: </strong>Thirty-seven patients (11.1%) showed no-reflow after primary PCI. High platelet-fibrin clot strength (P-FCS: ≥ 68 mm) measured by TEG was significantly associated with an increased risk of post-PCI \"no-reflow phenomenon\" (OR: 2.611; 95% CI: 1.220-5.584; P = 0.010). The risk stratification with \"no-reflow phenomenon\" and \"high P-FCS phenotype\" appeared to be additive to predict the risk of 3-year clinical event (log-rank P < 0.001 across the groups). Patients with both \"no-reflow phenomenon\" and high P-FCS had a higher risk of adverse clinical events compared with normal-reflow subjects with low P-FCS (adjusted HR: 6.654; 95% CI: 2.678-16.530; P < 0.001).</p><p><strong>Conclusions: </strong>This study demonstrated a close relationship between heightened thrombogenicity (assessed by TEG P-FCS) with \"no-reflow phenomenon,\" and their additive prognostic implications after primary PCI in STEMI patients. Effective control of clot strength may reduce the risk of \"no-reflow phenomenon\" and improve clinical outcomes in these patients. (Gyeongsang National University Hospital Registry [GNUH]; NCT04650529).</p>","PeriodicalId":73529,"journal":{"name":"JACC. Asia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jacasi.2025.07.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Following percutaneous coronary intervention (PCI), the "no-reflow phenomenon" is associated with a worse outcome. However, it remains unclear how to prevent and treat this phenomenon during PCI.
Objectives: This study aimed to evaluate the association between thrombogenicity profiles and "no-reflow phenomenon" during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI).
Methods: From a real-world registry, we prospectively enrolled patients with STEMI who underwent primary PCI (n = 334). Thrombolysis In Myocardial Infarction flow grade was assessed at final angiography, and the "no-reflow phenomenon" was defined as Thrombolysis In Myocardial Infarction flow between 0 and 2. Thrombogenicity profiles were assessed with thromboelastography (TEG) and conventional hemostatic measurements.
Results: Thirty-seven patients (11.1%) showed no-reflow after primary PCI. High platelet-fibrin clot strength (P-FCS: ≥ 68 mm) measured by TEG was significantly associated with an increased risk of post-PCI "no-reflow phenomenon" (OR: 2.611; 95% CI: 1.220-5.584; P = 0.010). The risk stratification with "no-reflow phenomenon" and "high P-FCS phenotype" appeared to be additive to predict the risk of 3-year clinical event (log-rank P < 0.001 across the groups). Patients with both "no-reflow phenomenon" and high P-FCS had a higher risk of adverse clinical events compared with normal-reflow subjects with low P-FCS (adjusted HR: 6.654; 95% CI: 2.678-16.530; P < 0.001).
Conclusions: This study demonstrated a close relationship between heightened thrombogenicity (assessed by TEG P-FCS) with "no-reflow phenomenon," and their additive prognostic implications after primary PCI in STEMI patients. Effective control of clot strength may reduce the risk of "no-reflow phenomenon" and improve clinical outcomes in these patients. (Gyeongsang National University Hospital Registry [GNUH]; NCT04650529).